Search

everythinglearnresearchcommunity

for

Search:↓

ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.

Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.

THAP1 gene changes do not affect DYT1 dystonia; finasteride may help reduce tics and OCD in Tourette syndrome.

JAK inhibitors like tofacitinib are effective and safer for severe alopecia areata than glucocorticosteroids.

The guidelines help doctors manage skin problems from certain cancer treatments to improve patients' lives.

Oral Janus kinase inhibitors may be an effective treatment option for lichen planopilaris with some risk of increased cholesterol and liver enzyme levels.

New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.

KY19382 helps to regrow hair and create new hair follicles.

Baricitinib and tofacitinib have different safety patterns in treating alopecia areata.

Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.

Mutations in iRhom2 affect hair and skin in mice and are linked to esophageal cancer, with ADAM17 playing a crucial role.

Janus Kinase inhibitors are effective and safe for treating alopecia areata, but more research is needed.

Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

JAK inhibitors show promise in treating moderate to severe alopecia areata.

Disrupting the Tsc2 gene in certain cells leads to thicker skin, larger hair, and changes in hair growth signaling, which can be partly reversed with specific treatment.

Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.

Topical Ruxolitinib may safely treat severe hair loss.

Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.

JAK inhibitors are effective for treating alopecia areata, with most patients seeing hair growth after treatment.

Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.

Blocking casein kinase 1 in skin cells can help melanocyte precursors move better, potentially helping with conditions like vitiligo or gray hair.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.

Activating PKM2 and Wnt/β-catenin signaling speeds up wound healing.

Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.

Rapamycin may help treat Leigh syndrome by targeting protein kinase C.